These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 26886334)
1. Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine. Ahmed KK; Geary SM; Salem AK J Pharm Sci; 2016 Mar; 105(3):1173-9. PubMed ID: 26886334 [TBL] [Abstract][Full Text] [Related]
2. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems. Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124 [TBL] [Abstract][Full Text] [Related]
3. Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine. Wafa EI; Geary SM; Ross KA; Goodman JT; Narasimhan B; Salem AK Nanomedicine; 2019 Oct; 21():102055. PubMed ID: 31319179 [TBL] [Abstract][Full Text] [Related]
5. M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity. Ma T; Wang L; Yang T; Ma G; Wang S Int J Pharm; 2014 Oct; 473(1-2):296-303. PubMed ID: 24984067 [TBL] [Abstract][Full Text] [Related]
6. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity. Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132 [TBL] [Abstract][Full Text] [Related]
7. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. Han R; Zhu J; Yang X; Xu H J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162 [TBL] [Abstract][Full Text] [Related]
8. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine. Jahan ST; Sadat SM; Haddadi A Int J Nanomedicine; 2018; 13():367-386. PubMed ID: 29391795 [TBL] [Abstract][Full Text] [Related]
9. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442 [TBL] [Abstract][Full Text] [Related]
10. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256 [TBL] [Abstract][Full Text] [Related]
11. Biodegradable Cationic Polycarbonates as Vaccine Adjuvants. Lee ALZ; Yang C; Gao S; Wang Y; Hedrick JL; Yang YY ACS Appl Mater Interfaces; 2020 Nov; 12(47):52285-52297. PubMed ID: 33179910 [TBL] [Abstract][Full Text] [Related]
12. In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A. Guldner D; Hwang JK; Cardieri MC; Eren M; Ziaei P; Norton MG; Souza CD PLoS One; 2016; 11(11):e0165477. PubMed ID: 27835636 [TBL] [Abstract][Full Text] [Related]
13. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy. Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883 [TBL] [Abstract][Full Text] [Related]
14. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213 [TBL] [Abstract][Full Text] [Related]
15. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response. Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266 [TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572 [TBL] [Abstract][Full Text] [Related]
17. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512 [TBL] [Abstract][Full Text] [Related]
18. Surface-assembled poly(I:C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and bystander cell stimulation. Hafner AM; Corthésy B; Textor M; Merkle HP Int J Pharm; 2016 Nov; 514(1):176-188. PubMed ID: 27863662 [TBL] [Abstract][Full Text] [Related]
19. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216 [TBL] [Abstract][Full Text] [Related]
20. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Hafner AM; Corthésy B; Merkle HP Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]